Mediwound (NASDAQ:MDWD) PT Lowered to $7.00 at Oppenheimer

Mediwound (NASDAQ:MDWD) had its target price decreased by Oppenheimer from $15.00 to $7.00 in a research report released on Wednesday, The Fly reports. Oppenheimer currently has an outperform rating on the biopharmaceutical company’s stock.

Several other analysts also recently issued reports on the stock. HC Wainwright initiated coverage on shares of Mediwound in a research report on Monday, August 5th. They issued a buy rating and a $5.50 price objective for the company. Zacks Investment Research raised shares of Mediwound from a sell rating to a hold rating in a research report on Friday, July 12th. Finally, ValuEngine raised shares of Mediwound from a sell rating to a hold rating in a research report on Thursday, August 1st. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Mediwound has an average rating of Buy and a consensus price target of $7.25.

Shares of NASDAQ:MDWD opened at $2.71 on Wednesday. The company has a market capitalization of $81.81 million, a PE ratio of -5.53 and a beta of 0.49. The company has a current ratio of 4.13, a quick ratio of 3.79 and a debt-to-equity ratio of 0.11. Mediwound has a twelve month low of $2.55 and a twelve month high of $6.75. The firm has a 50 day simple moving average of $3.22 and a 200-day simple moving average of $4.28.

Mediwound (NASDAQ:MDWD) last issued its quarterly earnings data on Tuesday, August 13th. The biopharmaceutical company reported ($0.12) earnings per share for the quarter, topping the consensus estimate of ($0.15) by $0.03. The business had revenue of $20.75 million during the quarter, compared to the consensus estimate of $7.03 million. Mediwound had a net margin of 70.54% and a negative return on equity of 156.56%. As a group, equities research analysts predict that Mediwound will post -0.58 EPS for the current fiscal year.

Institutional investors have recently added to or reduced their stakes in the company. Delek Group Ltd. bought a new stake in Mediwound in the first quarter valued at $141,000. Meitav Dash Investments Ltd. increased its stake in shares of Mediwound by 0.6% in the 1st quarter. Meitav Dash Investments Ltd. now owns 598,508 shares of the biopharmaceutical company’s stock valued at $2,993,000 after purchasing an additional 3,536 shares during the last quarter. Deutsche Bank AG increased its stake in shares of Mediwound by 73.5% in the 4th quarter. Deutsche Bank AG now owns 39,740 shares of the biopharmaceutical company’s stock valued at $161,000 after purchasing an additional 16,840 shares during the last quarter. Menta Capital LLC increased its stake in shares of Mediwound by 200.2% in the 1st quarter. Menta Capital LLC now owns 44,514 shares of the biopharmaceutical company’s stock valued at $223,000 after purchasing an additional 29,686 shares during the last quarter. Finally, Millennium Management LLC boosted its holdings in shares of Mediwound by 33.2% during the 4th quarter. Millennium Management LLC now owns 68,365 shares of the biopharmaceutical company’s stock valued at $278,000 after acquiring an additional 17,048 shares in the last quarter. Institutional investors own 31.16% of the company’s stock.

Mediwound Company Profile

MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products to address unmet needs. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns in the European Union, Israel, and Argentina.

Featured Story: How can investors find ex-dividend dates?

The Fly

Receive News & Ratings for Mediwound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mediwound and related companies with MarketBeat.com's FREE daily email newsletter.